What is Eikon Therapeutics, Inc. 's R&D?

Eikon Therapeutics, Inc. (EIKN) reported R&D of $70.05M in Q1 2026.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Eikon Therapeutics, Inc. EIKN R&D

R&D at other companies

BeldenBDC

$30.09M+5.9%

Cabot CorporationCBT

$14M-6.7%

RepligenRGEN

$14.46M+19.3%

Envista Holdings CorporationNVST

$30M+18.6%

VontierVNT

$41.4M+3.0%

Archer AviationACHR

$171.7M+65.6%

Other financials

Income statement

See full

Operating income-$87.3M-22.3%

Net income-$83.0M-21.6%

EPS (diluted)-$2.46+90.9%

Balance sheet

See full

Cash & equivalents$161.2M-21.2%

Total debt$254.8M—

Total equity$550.7M+186%

Total assets$850.8M—

Cash flow

See full

Operating cash flow-$89.8M-64.7%

CapEx$262.0K-98.8%

Free cash flow-$90.1M-17.1%

Valuation

See full

Market cap$514.86M—

Where this comes from

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Eikon Therapeutics, Inc. ’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eikon Therapeutics, Inc. 's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Eikon Therapeutics, Inc. 's R&D?: Eikon Therapeutics, Inc. (EIKN) reported R&D of $70.05M in Q1 2026.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.